Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | THRA | P10827 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | F9 | P00740 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL693518 | 0.84 | S1PR3 (0.50) | HIF1ASMPD1PTPN1S1PR3ALDH1A1 | |
| SCHEMBL692220 | 0.79 | HIF1A (0.47) | HIF1ASMN1; SMN2MAPTPTPN1ALDH1A1 | |
| SCHEMBL692489 | 0.78 | MAPK14 (0.45) | HIF1ASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL692923 | 0.76 | FFAR1 (0.45) | HIF1AMAPT | |
| SCHEMBL690828 | 0.75 | SMN1; SMN2 (0.48) | TP53SMN1; SMN2MAPTPTPN1ALDH1A1 | |
| SCHEMBL9611041 | 0.75 | MAPK1 (0.57) | TP53THRBALDH1A1MAPK1 | |
| SCHEMBL691568 | 0.74 | RAB9A (0.47) | SMN1; SMN2MAPTSMPD1THRBALDH1A1 | |
| SCHEMBL693635 | 0.74 | SMPD1 (0.50) | SMN1; SMN2SMPD1THRBS1PR3ALDH1A1 | |
| SCHEMBL692348 | 0.73 | MEN1 (0.49) | MAPK1 | |
| SCHEMBL9613113 | 0.72 | MAPK14 (0.46) | HIF1ASMN1; SMN2MAPTALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560643-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | Institute for OneWorld Health (US) | 2013-02-27 | — | — | EP | claimed |
| US-20120136003-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH | 2012-05-31 | — | — | US | claimed |
| EP-2421528-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | Institute for OneWorld Health (US) | 2012-02-29 | — | — | EP | claimed |
| US-20110288103-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH | 2011-11-24 | — | — | US | claimed |
| WO-2011133596-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2011-10-27 | — | — | WO | claimed |
| WO-2010123933-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2010-10-28 | — | — | WO | claimed |
| EP-2560643-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | Institute for OneWorld Health (US) | 2013-02-27 | — | — | EP | disclosed |
| US-20120136003-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH | 2012-05-31 | — | — | US | disclosed |
| US-20120136003-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH | 2012-05-31 | — | — | US | disclosed |
| US-20120136003-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH | 2012-05-31 | — | — | US | disclosed |
| EP-2421528-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | Institute for OneWorld Health (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20110288103-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH | 2011-11-24 | — | — | US | disclosed |
| US-20110288103-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH | 2011-11-24 | — | — | US | disclosed |
| US-20110288103-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH | 2011-11-24 | — | — | US | disclosed |
| WO-2011133596-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133596-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2010123933-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010123933-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136003-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | CFTR, PKD1, PKD2 | HIF1A 1855/4885P2RX7 370/4885TP53 1900/4885 |
| US-20110288103-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | ORAI1, ATP2A3, ANO1 | HIF1A 1373/4885P2RX7 303/4885TP53 3985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.